Published in Scientifica (Cairo) on February 03, 2013
Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection. PLoS Pathog (2014) 1.03
Immunology of Osteoporosis: A Mini-Review. Gerontology (2015) 0.88
Deregulation of bone forming cells in bone diseases and anabolic effects of strontium-containing agents and biomaterials. Biomed Res Int (2014) 0.85
The effects of α-tocopherol on bone: a double-edged sword? Nutrients (2014) 0.82
Osteoclasts and CD8 T cells form a negative feedback loop that contributes to homeostasis of both the skeletal and immune systems. Clin Dev Immunol (2013) 0.82
The Regulatory Roles of MicroRNAs in Bone Remodeling and Perspectives as Biomarkers in Osteoporosis. Biomed Res Int (2016) 0.82
Regulators of G protein signaling 12 promotes osteoclastogenesis in bone remodeling and pathological bone loss. Cell Death Differ (2015) 0.81
Targeting stem cell niche can protect hematopoietic stem cells from chemotherapy and G-CSF treatment. Stem Cell Res Ther (2015) 0.81
Fibulin-1 is required for bone formation and Bmp-2-mediated induction of Osterix. Bone (2014) 0.80
Effects of plyometric exercise session on markers of bone turnover in boys and young men. Eur J Appl Physiol (2015) 0.80
Renal and Gastrointestinal Considerations in Joint Replacement Surgery. J Nat Sci (2015) 0.79
Ectopic osteoid and bone formation by three calcium-phosphate ceramics in rats, rabbits and dogs. PLoS One (2014) 0.79
Inflammation as a Therapeutic Target for Diabetic Neuropathies. Curr Diab Rep (2016) 0.78
Increased NF-κB Activity and Decreased Wnt/β-Catenin Signaling Mediate Reduced Osteoblast Differentiation and Function in ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mice. J Biol Chem (2015) 0.78
Recent developments in metabolic bone diseases: a gnathic perspective. Head Neck Pathol (2014) 0.78
The alliance of mesenchymal stem cells, bone, and diabetes. Int J Endocrinol (2014) 0.78
Both immune hormone IL-10 and parathormone tend to increase in serum of old osteoporotic people independently of 1, 25 dihydroxy vitamin D3. Caspian J Intern Med (2016) 0.77
Sphingosine-1-Phosphate Receptor 2 Regulates Proinflammatory Cytokine Production and Osteoclastogenesis. PLoS One (2016) 0.77
HDL-Associated Paraoxonase 1 as a Bridge between Postmenopausal Osteoporosis and Cardiovascular Disease. Chonnam Med J (2014) 0.76
The Wnt inhibitor dickkopf-1: a link between breast cancer and bone metastases. Clin Exp Metastasis (2015) 0.76
Antihormonal treatment associated musculoskeletal pain in women with breast cancer in the adjuvant setting. Onco Targets Ther (2016) 0.75
Differentiation of deer tendons from cattle tendons by a loop-mediated isothermal amplification (LAMP) test and bone remodeling bioassays. Chin Med (2015) 0.75
Osteoimmunology and Beyond. Curr Med Chem (2016) 0.75
Evaluation of bone mineral density and 25-hydroxyvitamin D levels in subjects with silica exposure. Environ Health Prev Med (2016) 0.75
Mandibular regeneration after immediate load dental implant in a periodontitis patient: A clinical and ultrastructural case report. Medicine (Baltimore) (2017) 0.75
Charcot stage 0: A review and consideratons for making the correct diagnosis early. Clin Diabetes Endocrinol (2015) 0.75
The Cell Surface Markers Expression in Postmenopausal Women and Relation to Obesity and Bone Status. Int J Environ Res Public Health (2017) 0.75
High doses of vitamin C plus E reduce strength training-induced improvements in areal bone mineral density in elderly men. Eur J Appl Physiol (2017) 0.75
Is osteoporosis an autoimmune mediated disorder? Bone Rep (2017) 0.75
Assessment of bone metabolism and biomechanical properties of the femur, following treatment with anastrozole and letrozole in an experimental model of menopause. Oncol Lett (2017) 0.75
Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults. Osteoporos Int (2017) 0.75
A translational approach from an animal model identifies CD80 as a candidate gene for the study of bone phenotypes in postmenopausal women. Osteoporos Int (2017) 0.75
Bone mineral density in people living with HIV: a narrative review of the literature. AIDS Res Ther (2017) 0.75
Analysis of Nkx3.1:Cre-driven Erk5 deletion reveals a profound spinal deformity which is linked to increased osteoclast activity. Sci Rep (2017) 0.75
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser (1994) 17.37
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res (2007) 14.84
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med (2004) 14.53
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Bone resorption by osteoclasts. Science (2000) 11.68
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int (2006) 11.05
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA (2004) 10.40
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (1997) 8.59
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 7.81
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev (1999) 7.69
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 7.66
Homeostasis of naive and memory T cells. Immunity (2008) 7.48
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature (2000) 6.49
Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev (2000) 6.42
Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev (2002) 6.38
HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med (2011) 6.30
Differential requirements for survival and proliferation of CD8 naïve or memory T cells. Science (1997) 6.28
Differences in mortality after fracture of hip: the east Anglian audit. BMJ (1995) 6.12
The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity (1999) 6.10
Rheumatoid arthritis. Cell (1996) 6.01
TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest (2000) 5.78
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
Matrix-embedded cells control osteoclast formation. Nat Med (2011) 5.77
Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med (1997) 5.72
Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med (2011) 5.66
Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS (2006) 5.58
Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med (1995) 5.27
Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med (2008) 5.14
Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med (2000) 5.02
TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med (2009) 4.58
Minireview: the OPG/RANKL/RANK system. Endocrinology (2001) 4.47
Age and bone mass as predictors of fracture in a prospective study. J Clin Invest (1988) 4.46
Osteoblastic cells are involved in osteoclast formation. Endocrinology (1988) 4.37
Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab (2008) 3.64
Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest (1999) 3.60
TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med (1997) 3.59
IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest (2005) 3.56
Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell (2004) 3.55
Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest (2006) 3.45
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology (2005) 3.42
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone (2007) 3.41
Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest (1992) 3.40
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis (2010) 3.37
Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med (2002) 3.34
Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest (2000) 3.15
Transforming growth factor-beta1 to the bone. Endocr Rev (2005) 3.13
From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev (2010) 3.11
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med (1999) 3.07
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev (2005) 3.01
Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med (1996) 2.92
Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun (1997) 2.81
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr (2009) 2.75
Bone disease and HIV infection. Clin Infect Dis (2005) 2.71
Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone (1999) 2.69
Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem (2004) 2.66
Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol (2001) 2.65
Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A (2001) 2.56
B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol (2006) 2.56
Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med (2009) 2.51
Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med (Berl) (2005) 2.48
Prevention and management of osteoporosis. World Health Organ Tech Rep Ser (2003) 2.48
Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci U S A (1991) 2.44
Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology (1995) 2.44
Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem (2003) 2.44
The economic cost of hip fractures in community-dwelling older adults: a prospective study. J Am Geriatr Soc (1997) 2.40
A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest (2003) 2.37
Osteoimmunology: interactions of the bone and immune system. Endocr Rev (2008) 2.32
Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med (2009) 2.30
Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun (1999) 2.28
An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci U S A (2001) 2.28
Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene (2003) 2.22
Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis (2010) 2.20
Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis (2003) 2.20
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med (2000) 2.20
Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol (2007) 2.17
B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood (2007) 2.16
IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest (2006) 2.15
Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med (1995) 2.15
Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet (2000) 2.13
BMP signaling in skeletal development. Biochem Biophys Res Commun (2005) 2.13
Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology (2000) 2.13
Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem (2001) 2.13
Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum (2007) 2.12
Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One (2011) 2.11
Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem (2012) 2.08
B lymphocyte dysfunctions in HIV infection. Curr HIV Res (2004) 2.07
B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol (2007) 2.05
The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev (2005) 2.03
Bone structure: from angstroms to microns. FASEB J (1992) 2.03
Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity (1998) 2.02
Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest (1994) 2.00